Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 860 participants.
Also called NCT03496883
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 860 participants
- Registry
-
NCT03496883 -
2019-003722-25
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, Germany, Japan, Spain, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03496883. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-03 (actual); primary completion 2028-01-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
- Acronym
- FASTEST
- Condition
- Intracerebral Hemorrhage
- Intervention (Biological)
- Recombinant Activated Factor VII (rFVIIa)
- Intervention (Biological)
- Placebo
- Lead sponsor
- Joseph Broderick, MD
- Collaborator
- Novo Nordisk A/S
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
Record details
- Record id
cardio:ct-nct03496883- Content hash
78010e774da590b2f305c9261b9b7efe2903146d4846389c4472038bfe5d59a8